SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: arnie h who wrote (1004)2/17/2000 10:41:00 AM
From: Filbert  Read Replies (2) of 1386
 
Arnie,

I sort of half-agree <g>. They could plan the Phase III's with their staff and advisory board, get buy-in on the plan from the FDA, and then farm out the work to a firm that specializes in performing the clinicals, but I think the cost would be prohibitive. I am unfamilar with the costs of farming out a trial of that sort however. And of course the staff has to be paid and research/development continued while the trial is ongoing, and the Alrex/Lotemax money is not at that level . . . yet (written with much hope for the future; maybe too much <g>).

Filbert
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News